FDA Approves First Therapy to Reduce Pancreatitis Risk - Top-Institutions - MDSpire

FDA Approves First Therapy to Reduce Pancreatitis Risk

In two placebo-controlled trials, triglyceride levels declined by up to 72% compared with placebo.

  • By

  • Kathryn Wighton

  • June 24, 2026

  • 2 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Gastroenterology

  • #2

    American Association for the Study of Liver Disease
    American Association for the Study of Liver Disease

    Alexandria, Virginia

    Key Differentiators

    • Gastroenterology

  • #3

    American Gastroenterological Association
    American Gastroenterological Association

    Bethesda, Maryland

    Key Differentiators

    • Gastroenterology

  • #4

    University of Pennsylvania’s Scheie Eye Institute
    University of Pennsylvania’s Scheie Eye Institute

    Philadelphia, Pennsylvania

    Key Differentiators

    • Gastroenterology

  • #5

    SIOPEL 6
    SIOPEL 6

    N/A, N/A

    Key Differentiators

    • Gastroenterology

Original Source(s)

FDA Approves First Therapy to Reduce Pancreatitis Risk

  • by Kathryn Wighton

  • June 24, 2026

Related Content

Peptides Are Outrunning the Rulebook

A new JAMA Viewpoint argues US drug policy is built for a market that no longer behaves like one.

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.